 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C10H17NO2 |
| Molar mass | 183.251 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
PD-217,014 is a drug developed byPfizer and related togabapentin, which similarly binds to the α2δcalcium channels (1 and2). It was developed as a potentially more potent successor to gabapentin andpregabalin, along with several other analogues such asatagabalin and4-methylpregabalin, but while PD-217,014 produces visceral analgesic effects in animal studies with higher potency and efficacy than gabapentin, it was not developed further for clinical use because of its comparatively more complex synthesis, compared to other related analogues.[1]
